Copyright © 2021. Inderes Oyj. All rights reserved.
Käyttäjätili

Hei anonyymi!

Luomalla maksuttoman Inderes-tilin, pääset käsiksi Inderesin analyysiin, voit tilata suositun aamukatsauksen ja seurata sinua kiinnostavia yhtiöitä sekä keskusteluita.

Luo tili

Onko sinulla jo Inderes-tili?

ExpreS2ion Biotech Holding

Analyytikko

Sisäpiirin kaupat

Nettovaikuttavuus

Tiedotteet
18.11.
2022

Hørsholm, Denmark, November 18, 2022 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion") announces that Pareto Securities and Analysguiden have both published research reports on ExpreS2ion in November. Pareto reiterated its SEK 25 price target while Analysguiden reduced its price target to SEK 25 per share from SEK 30 per share. Furthermore, a filmed company presentation by CEO Bent U. Frandsen and CFO Keith Alexander, hosted by H.C.

Tiedotteet
17.11.
2022

Hørsholm, Denmark, November 17, 2022 - ExpreS2ion Biotech Holding AB ("ExpreS2ion") today announces its third quarter financial results for 2022. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.

CEO Bent U. Frandsen comments

Tiedotteet
15.11.
2022

Hørsholm, Denmark, November 15, 2022 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion") will participate and hold presentations at key industry and investor events in the coming month. These include PEGS Europe Protein & Antibody Engineering Summit (November 14-16), the presentation of Q3 2022 results (November 17), and the BioStock Life Science Summit 2022 (November 29-30). 

Tiedotteet
3.11.
2022

Hørsholm, Denmark, November 3, 2022 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion") today announces the establishment of an Oncology Scientific Advisory Board (OSAB). The six initial members of the ExpreS2ion OSAB bring a depth of knowledge in oncology, breast cancer, clinical trials and therapeutic HER2 vaccines, and will contribute to the development of ExpreS2ion's proprietary HER2-cVLP breast cancer vaccine, ES2B-C001.

Tiedotteet
24.10.
2022

Hørsholm, Denmark, October 24, 2022 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion") announces that the journal Biomedicines published an article about the breast cancer vaccine candidate ES2B-C001 titled "Prevention and therapy of metastatic HER-2+ mammary carcinoma with a human candidate HER-2 virus-like particle vaccine".

Abstract excerpt: "…ES2B-C001 is a promising candidate vaccine for the therapy of tumors expressing HER-2. Preclinical results warrant further development towards human clinical studies."

Tiedotteet
17.10.
2022

Hørsholm, Denmark, October 17, 2022 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion") announces that follow-up results from Bavarian Nordic's Phase II clinical trial for the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 booster vaccine show that antibody titers remained high at levels associated with greater than 90% efficacy six months after vaccination for both the Wuhan and the Omicron variant.

Tiedotteet
7.10.
2022

Hørsholm, Denmark, October 7, 2022 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion") announces that Bavarian Nordic's ongoing Phase III clinical trial to evaluate the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 booster vaccine, which started to include subjects in the United States in September, will also start to include subjects in Denmark in October. The Danish part of the study will be conducted at hospitals on Zealand, Jutland and Funen.

Tiedotteet
6.10.
2022

Hørsholm, Denmark, October 6, 2022 - ExpreS2ion Biotech Holding AB ("ExpreS2ion") today announces that Allan Rosetzsky, with immediate effect, has decided to resign from ExpreS2ion's board of directors. Hereafter the board of directors will consist of Martin Roland Jensen (Chair), Jakob Knudsen, Karin Garre, and Sara Sande.

Tiedotteet
27.9.
2022

Hørsholm, Denmark, September 27, 2022 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion") announces that a filmed company presentation by CEO Bent U. Frandsen at Aktiedagen Lund in which he presents provides an update on ExpreS2ion's powerful technology platform for vaccine development, pipeline projects, and key financial figures, is now available on the company's website.

Tiedotteet
22.9.
2022

Hørsholm, Denmark, September 22, 2022 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion") announces that Pareto Securities has published a new research report on ExpreS2ion in September in which a new analyst, Marietta Miemietz, assumes coverage of the Company. 

ExpreS2ion Biotech Holding

ipo